FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804096699> ?p ?o ?g. }

• W2804096699 endingPage "1859" @default.
• W2804096699 startingPage "1858" @default.
• W2804096699 abstract "Desogestrel is known to be commonly associated with mood changes, depressed mood and decreased libido 1. Anxiety and panic attacks have however not yet been described with desogestrel use. In this letter, we highlight the potential relationship between desogestrel and panic attacks, which has been described by mainly patients and some health care professionals in spontaneous reports [individual case safety reports (ICSRs)] from VigiBase, the WHO global database of ICSRs 2, 3. Contraceptive drugs are commonly used worldwide. Desogestrel is a hormonal progestin used as monotherapy or in combination with ethinylestradiol. The contraceptive effect is, in contrast to traditional progestogen-only pills, achieved primarily by inhibition of ovulation 1. A panic attack is defined as a discrete period of intense fear or discomfort, often accompanied by physical symptoms such as palpitations and trembling. Experiencing repeated, consistent panic attacks that get in the way of everyday functioning is considered a defining symptom of panic disorder 4. In VigiBase, there are a total of 25 reports for panic attacks and disorders [MedDRA high level term (HLT)] for desogestrel used as monotherapy reported between 2003 and October 2017. These reports were identified in a signal detection screening activity focusing on reports received primarily from patients. In the case series, 19 out of 22 reports, which had mentioned the qualification of the reporter, originated from consumers or nonhealth professionals. A disproportionality measure was used to highlight potential signals, and for this particular drug and ADR (MedDRA preferred term panic attacks), 1 case of panic attacks was expected but as many as 17 were reported 5. A subsequent search in VigiBase revealed eight additional reports for the MedDRA HLT panic attacks and disorders. In all reports, the causality was individually assessed. The well-described reports are all from Europe and concern women between 18 to 48 years (median age 30). In 17 cases, desogestrel is the only drug reported to have been used. Of the eight other reports that had additional drugs reported, only three reports suspected another drug in addition to desogestrel for the reaction. Ethinylestradiol/levonorgestrel was co-suspected and possibly contributing to the panic attack in two cases while in the third case, the co-suspected drug, lymecycline, was unlikely contributing to the reported event. Only one patient had a documented medical history of panic attacks but she had not had a panic attack for five years. Fifteen days after starting desogestrel, she experienced a panic attack. In 11 reports, it was documented that the panic attacks occurred within 2 months of starting the contraceptive drug. The median time from start of drug intake to occurrence of the panic reactions, in the reports where such information was available, was 15 days. Commonly co-reported terms were anxiety (15 reports) and depression (7 reports). In 17 cases, the patients were reported to be recovering/have recovered (one with sequelae) after withdrawal of the drug and in one case psychiatric problems (not further specified) reoccurred when the drug was started again. In five cases, it was reported that the patients had not recovered from the panic attacks at the time of reporting. Eighteen reports were classified as serious among the 22 reports that had added information about the seriousness of the case. Severe depression, anxiety and panic attacks. Sought additional treatment for depression/anxiety from general practitioner but symptoms abated once stopped taking Cerazette®. Episodes of anxiety, panic and panic attacks in pressured situations. I connected this to my current life situation before I stopped Cerazette® …. At the same time the panic attacks I anticipated in certain situations did not occur. I did never suspect Cerazette® to have any role in my anxiety or panic attacks before I stopped the drug and realized that my problems went away. The link with the drug as a cause for the panic attacks were often only identified after the patient had stopped taking desogestrel. This association has not to our knowledge been highlighted as a suspected ADR in the scientific literature previously. However, a structurally similar progestin, levonorgestrel, has been described to cause panic disorder in two cases. In both cases, the panic disorder occurred within 1–2 months after inserting levonorgestrel as a contraceptive device 6. It is important to communicate the potential risks of anxiety and panic attacks while using desogestrel, which can have major impact on the daily functioning of a person. As the consumers of contraceptive drugs are mainly otherwise healthy women, the acceptance of undesirable adverse reactions is low. With this letter, we would like to ask prescribers and consumers of desogestrel to consider the possibility that desogestrel could be a possible cause for any anxiety or panic attacks experienced while using the drug. There are no competing interests to declare. The authors are indebted to the national centres who make up the WHO Programme for International Drug Monitoring and contribute reports to VigiBase. However, the opinions and conclusions of this study are not necessarily those of the various centres nor of the WHO." @default.
• W2804096699 created "2018-06-01" @default.
• W2804096699 creator A5023164482 @default.
• W2804096699 creator A5027051500 @default.
• W2804096699 date "2018-05-24" @default.
• W2804096699 modified "2023-10-10" @default.
• W2804096699 title "Desogestrel and panic attacks - a new suspected adverse drug reaction reported by patients and health care professionals on spontaneous reports" @default.
• W2804096699 cites W2167186282 @default.
• W2804096699 doi "https://doi.org/10.1111/bcp.13617" @default.
• W2804096699 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6046470" @default.
• W2804096699 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29797731" @default.
• W2804096699 hasPublicationYear "2018" @default.
• W2804096699 type Work @default.
• W2804096699 sameAs 2804096699 @default.
• W2804096699 citedByCount "6" @default.
• W2804096699 countsByYear W28040966992019 @default.
• W2804096699 countsByYear W28040966992020 @default.
• W2804096699 countsByYear W28040966992023 @default.
• W2804096699 crossrefType "journal-article" @default.
• W2804096699 hasAuthorship W2804096699A5023164482 @default.
• W2804096699 hasAuthorship W2804096699A5027051500 @default.
• W2804096699 hasBestOaLocation W28040966991 @default.
• W2804096699 hasConcept C118552586 @default.
• W2804096699 hasConcept C197934379 @default.
• W2804096699 hasConcept C199475168 @default.
• W2804096699 hasConcept C2777529043 @default.
• W2804096699 hasConcept C2779076696 @default.
• W2804096699 hasConcept C2779441745 @default.
• W2804096699 hasConcept C2780035454 @default.
• W2804096699 hasConcept C2780712732 @default.
• W2804096699 hasConcept C2780733359 @default.
• W2804096699 hasConcept C2908647359 @default.
• W2804096699 hasConcept C2986817661 @default.
• W2804096699 hasConcept C558461103 @default.
• W2804096699 hasConcept C57658597 @default.
• W2804096699 hasConcept C71924100 @default.
• W2804096699 hasConcept C98274493 @default.
• W2804096699 hasConcept C99454951 @default.
• W2804096699 hasConceptScore W2804096699C118552586 @default.
• W2804096699 hasConceptScore W2804096699C197934379 @default.
• W2804096699 hasConceptScore W2804096699C199475168 @default.
• W2804096699 hasConceptScore W2804096699C2777529043 @default.
• W2804096699 hasConceptScore W2804096699C2779076696 @default.
• W2804096699 hasConceptScore W2804096699C2779441745 @default.
• W2804096699 hasConceptScore W2804096699C2780035454 @default.
• W2804096699 hasConceptScore W2804096699C2780712732 @default.
• W2804096699 hasConceptScore W2804096699C2780733359 @default.
• W2804096699 hasConceptScore W2804096699C2908647359 @default.
• W2804096699 hasConceptScore W2804096699C2986817661 @default.
• W2804096699 hasConceptScore W2804096699C558461103 @default.
• W2804096699 hasConceptScore W2804096699C57658597 @default.
• W2804096699 hasConceptScore W2804096699C71924100 @default.
• W2804096699 hasConceptScore W2804096699C98274493 @default.
• W2804096699 hasConceptScore W2804096699C99454951 @default.
• W2804096699 hasIssue "8" @default.
• W2804096699 hasLocation W28040966991 @default.
• W2804096699 hasLocation W28040966992 @default.
• W2804096699 hasLocation W28040966993 @default.
• W2804096699 hasOpenAccess W2804096699 @default.
• W2804096699 hasPrimaryLocation W28040966991 @default.
• W2804096699 hasRelatedWork W1993705965 @default.
• W2804096699 hasRelatedWork W2040883278 @default.
• W2804096699 hasRelatedWork W2072508645 @default.
• W2804096699 hasRelatedWork W2113520112 @default.
• W2804096699 hasRelatedWork W2158415380 @default.
• W2804096699 hasRelatedWork W2385245960 @default.
• W2804096699 hasRelatedWork W2443227885 @default.
• W2804096699 hasRelatedWork W2804096699 @default.
• W2804096699 hasRelatedWork W2992606933 @default.
• W2804096699 hasRelatedWork W3142260060 @default.
• W2804096699 hasVolume "84" @default.
• W2804096699 isParatext "false" @default.
• W2804096699 isRetracted "false" @default.
• W2804096699 magId "2804096699" @default.
• W2804096699 workType "article" @default.